Jeffrey K. Aronson

Jeffrey K. Aronson

Auto-generated profile, based on publicly available information

Jeffrey K. Aronson

Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
DRDavid S. Riley
David S. Riley
MBMelissa S. Barber
Melissa S. Barber
GKGunver S. Kienle
Gunver S. Kienle
JAJeffrey K. Aronson
Jeffrey K. Aronson
TSTido von Schoen-Angerer
Tido von Schoen-Angerer
JGJoel J. Gagnier
Joel J. Gagnier

25 April 2016 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
JAJeffrey K. Aronson
Jeffrey K. Aronson

14 July 2021 in BMJ
Verified
Journal Article
Open access
PDF file
TCTing Cai
Ting Cai
LALucy Abel
Lucy Abel
OLOliver Langford
Oliver Langford
GMGenevieve Monaghan
Genevieve Monaghan
JAJeffrey K Aronson
Jeffrey K Aronson
JSJames P Sheppard
James P Sheppard
Objective: To assess the associations between statins and adverse events in primary prevention of cardiovascular disease and to examine how the associations vary by type and dosage of statins. Design: Systematic review and meta-analysis. Data sources: Studies were identified from previous systematic reviews and searched in Medline, Embase, and the Cochrane Central Register of Controlled Trials, up to August 2020. Review methods: Randomised controlled trials in adults without a history of cardiovascular disease that compared statins with non-statin controls or compared different types or dosages of statins were included. Main outcome measures: Primary outcomes were common adverse events: self-reported muscle symptoms, clinically confirmed muscle disorders, liver dysfunction, renal insufficiency, diabetes, and eye conditions. Secondary outcomes included myocardial infarction, stroke, and death from cardiovascular disease as measures of efficacy. Data synthesis: A pairwise meta-analysis was conducted to calculate odds ratios and 95% confidence intervals for each outcome between statins and non-statin controls, and the absolute risk difference in the number of events per 10 000 patients treated for a year was estimated. A network meta-analysis was performed to compare the adverse effects of different types of statins. An E max model based meta-analysis was used to examine the dose-response relationships of the adverse effects of each statin. Results: 62 trials were included, with 120 456 participants followed up for an average of 3.9 years. Statins were associated with an increased risk of self-reported muscle symptoms (21 trials, odds ratio 1.06 (95% confidence interval 1.01 to 1.13); absolute risk difference 15 (95% confidence interval 1 to 29)), liver dysfunction (21 trials, odds ratio 1.33 (1.12 to 1.58); absolute risk difference 8 (3 to 14)), renal insufficiency (eight trials, odds ratio 1.14 (1.01 to 1.28); absolute risk difference 12 (1 to 24)), and eye conditions (six trials, odds ratio 1.23 (1.04 to 1.47); absolute risk difference 14 (2 to 29)) but were not associated with clinically confirmed muscle disorders or diabetes. The increased risks did not outweigh the reduction in the risk of major cardiovascular events. Atorvastatin, lovastatin, and rosuvastatin were individually associated with some adverse events, but few significant differences were found between types of statins. An E max dose-response relationship was identified for the effect of atorvastatin on liver dysfunction, but the dose-response relationships for the other statins and adverse effects were inconclusive. Conclusions: For primary prevention of cardiovascular disease, the risk of adverse events attributable to statins was low and did not outweigh their efficacy in preventing cardiovascular disease, suggesting that the benefit-to-harm balance of statins is generally favourable. Evidence to support tailoring the type or dosage of statins to account for safety concerns before starting treatment was limited. Systematic review registration: PROSPERO CRD42020169955.

25 February 2021 in BMJ Evidence-Based Medicine
Verified
Journal Article
Open access
PDF file
KTKathryn S Taylor
Kathryn S Taylor
KMKamal R Mahtani
Kamal R Mahtani
JAJeffrey K Aronson
Jeffrey K Aronson

16 December 2019 in Drug Safety
Verified
Journal Article
Closed access
PDF file
JAJeffrey K. Aronson
Jeffrey K. Aronson
CHCarl Heneghan
Carl Heneghan
RFRobin E. Ferner
Robin E. Ferner

1 May 2020 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
JAJeffrey K. Aronson
Jeffrey K. Aronson
AGA. Richard Green
A. Richard Green
We define a me‐too drug as a pharmacologically active compound that is structurally related to a first‐in‐class compound, regarded as belonging to the same therapeutic class as the original compound, and used for the same therapeutic purposes, but which may differ in some respects, such as specificity of pharmacological action, adverse reactions profile, or drug–drug interactions. We also offer definitions of related terms, including follow‐on drug and first‐in‐class. The therapeutic advantages of me‐too drugs may include improved target specificity, reduced risks of off‐target adverse reactions and drug–drug interactions, increased chance of benefit in some patients, and improved drug delivery and pharmacokinetics. Me‐too drugs can also demonstrate incremental innovation. Their availability may help in coping with drug shortages. However, they may occasionally cause unexpected adverse reactions that are not class effects. Tricyclic antidepressants, β‐blockers, and statins illustrate the diversity of me‐too drugs. Earlier compounds may be as effective as later ones, or more so. Tricyclic antidepressants have similar chemical structures, and compounds introduced after the first‐in‐class compound (imipramine) mostly offered little in the way of innovative features, but continue to be prescribed. In contrast, me‐too β‐blockers introduced after the first‐in‐class compound, pronethalol, have diverse structures and display several innovative features. Stereoisomers and biosimilars/biobetters provide special examples of me‐too drugs. Although many me‐too drugs offer no significant advantages over their predecessors, over 60% of the drugs listed on the World Health Organization's essential list are me‐toos. Different countries may choose different me‐too drugs when constructing essential medicines lists, partly explaining transnational differences between them.